Skip to main content
Equibles
ALURW logo

ALURW · Allurion Technologies, Inc. · Investor Relations

Track ALURW — free

Use ALURW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALURW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Oct 13
Rebalance outlook locked
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the amount and timing of such financings are uncertain, the Company has concluded that management’s plans do not alleviate substantial doubt about its ability to continue as a going concern for a reasonable period of time.”
View the 10-Q filed May 15, 2026
Market Cap
$2.01M
Shares
1.00M
Volume · Oct 13 9306 Avg daily vol (19 sessions) 40.39K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-03-02 Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
2026-02-24 Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
2026-02-23 Allurion Receives U.S. FDA Approval
2026-02-03 Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
2026-01-12 Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
2025-11-25 Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
2025-11-20 New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
2025-11-18 Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
2025-11-12 Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-11 Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Past events

Date Event Type
2025-11-12 Allurion Third Quarter Earnings Call Earnings call
2025-08-13 Allurion Second Quarter Earnings Call Earnings call
2025-06-04 Jefferies Global Healthcare Conference Conference
2025-05-14 Allurion First Quarter Earnings Call Earnings call
2025-03-26 Allurion Fourth Quarter Earnings Call Earnings call
2025-03-03 TD Cowen's 45th Annual Health Care Conference Conference
2024-11-13 Allurion Third Quarter Earnings Call Earnings call
2024-08-13 Allurion Second Quarter Earnings Call Earnings call
2024-06-13 Sidoti Small Cap Virtual Conference Conference
2024-06-05 Jefferies Global Healthcare Conference Conference
2024-05-14 Allurion First Quarter Earnings Call Earnings call
2024-03-21 Allurion Fourth Quarter Earnings Call Earnings call
2024-03-13 34th Annual Oppenheimer Healthcare MedTech & Services Conference Conference
2024-03-05 Cowen’s 44th Annual Health Care Conference Conference
2023-11-13 Allurion Third Quarter Earnings Call Earnings call
2023-06-07 Jefferies Healthcare Conference Conference

Source: https://investors.allurion.com/secure.aspx?return=%2foverview%2fdefault.aspx

Key facts CIK 1964979 CUSIP 02008G300 Visit website Investor relations